IPO Status: Closed [27th Jul 2021 to 29th Jul 2021]
Glenmark Lifesciences Limited, a leading Active Pharmaceutical Ingredients (API) manufacturer IPO of ₹ 1513.60 Cr opens on 27 July and closes on 29 July. The face value per share is Rs. 2, and the price band is fixed at Rs. 695-720. The floor price is 347.50 times and cap price is 360 times the face value. The lot size of the IPO is 20 shares. Stay tuned with us to know the opening and closing dates, price band, IPO lot size, and more.
|IPO Issue Opening Date:||27th Jul 2021|
|IPO Issue Closing Date:||29th Jul 2021|
|IPO Issue Price:||₹695-720 Per Share|
|IPO Listing At:||BSE, NSE|
|IPO Issue Type:||Book Build Issue|
|IPO Issue Size:||₹1513.60 Cr|
|Offer for Sale:||₹453.60 Cr|
|Fresh Issue:||₹1060 Cr.|
|Face Value:||₹2 Per Equity Share|
|Promoter Holding Pre IPO:||100%|
|Promoter Holding Post IPO:||82.84%|
|Allotment Status:||Allotment Status|
In this section we have covered all important dates related to Glenmark Life Sciences IPO. Dates are updated as they are announced. The most noted dates are IPO start date and IPO end date, which one should use to participate in IPO.
|Basis of Allotment Date*||3rd Aug 2021|
|Refunds Initiation*||4th Aug 2021|
|Credit of Shares to Demat*||5th Aug 2021|
|IPO Listing Date*||6th Aug 2021|
* - Tentative Dates
|Market Lot:||20 Shares|
|1 Lot Amount:||₹14400|
|Min Small HNI Lots(2-10 Lakh):||280 shares(14 lots)|
|Min Big HNI Lots(10+ Lakh):|
Glenmark Life Sciences Limited has established strong footprint in Active Pharmaceutical Ingredients manufacturing. The company manufactures high-quality APIS for different diseases like cardiovascular disease, central nervous system disease, pain management, diabetes, gastrointestinal disorders, anti-infectives, and others. It operates in business verticals; Generic APIs (Generic and Complex) and CDMO (Contract Development and Manufacturing operations) to serve specialty pharmaceutical companies.
Glenmark sells its products in India as well as other countries like Europe, Japan, Latin America, North America, etc. It has 4 manufacturing plants; 2 are in Gujarat and 2 are in Maharashtra. As of December 31, 2020, the manufacturing facilities have an aggregate installed capacity of 728.8 KL.
|Incorporation||Sector||IPO Issue Size||Website|
The table below is live update of IPO bidding details from NSE and BSE.
|# of Shares Offered||4,242,379 (28.25%)||3,232,770 (21.53%)||7,543,130 (50.23%)||15,018,279||1||27th Jul 2021 17:02||0.00x||0.86x||5.17x||2.78x||2||28th Jul 2021 17:03||1.38x||3.39x||9.28x||5.78x||3||29th Jul 2021 17:03||36.97x||122.54x||14.63x||44.17x|
Past performance and financial results of Glenmark Life Sciences.
|Glenmark Life Sciences Limited Financials||31-Mar-2021||31-Mar-2020||31-Mar-2019|
|Total Assets||₹1,997.08 Cr||₹1,725.60 Cr||₹1,475.40 Cr|
|Total Income||₹1,885.98 Cr||₹1,549.30 Cr||₹886.87 Cr|
|Net Profit/Loss||₹351.58 Cr||₹313.10 Cr||₹195.59 Cr|
Last Updated on 2021-09-27T10:41:33+00:00
Free Delivery for Lifetime
Flat ₹15 Per Trade in F&O
Rs 0 Demat AMC
FREE Account Opening (
Trade at Flat ₹20 per Trade Pay-as-you-go Demat AMC
Flat ₹20 Per Trade
Free Trading Tips & Software